Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients
Table 2
The comparison between the one-stage assay versus chromogenic assay for the measurement of factor VIII levels in the individual cases.
Patient ID
Age
N
One-stage assay†
Chromogenic assay†
Mean difference
SE
value
95% CI
Patient 1
25
5
0.04 (0.06)
0.23 (0.15)
−0.19
0.04
0.009
−0.31 to −0.08
Patient 2
24
4
0.03 (0.05)
0.15 (0.03)
−0.12
0.04
0.063
−0.25 to 0.012
Patient 3
57
4
0.34 (0.37)
0.46 (0.48)
−0.11
0.05
0.123
−0.29 to 0.05
Patient 4
32
5
0.01 (0.01)
0.12 (0.07)
−0.11
0.03
0.03
−0.20 to −0.17
Patient 5
28
5
0.05 (0.05)
0.04 (0.05)
0.004
0.002
0.178
−0.002 to 0.01
Patient 6
24
4
0.05 (0.06)
0.05 (0.07)
−0.002
0.002
0.391
−0.010 to 0.005
Patient 7
10
1
0.04
0.09
−0.05
NA
NA
NA
Patient 8
30
5
0.06 (0.08)
0.14 (0.13)
−0.076
0.025
0.040
−0.14 to −0.005
Patient 9
26
2
0.01 (0.11)
0.14 (0.14)
−0.045
0.025
0.323
−0.36 to 0.27
Patient 10
34
5
0.06 (0.08)
0.07 (0.09)
−0.008
0.007
0.033
−0.02 to −0.12
Patient 11
36
7
0.03 (0.04)
0.04 (0.04)
−0.005
0.002
0.103
−0.01 to −0.001
Patient 12
29
5
0.12 (0.14)
0.17 (0.19)
−0.052
0.024
0.104
−0.12 to 0.016
Patient 13
10
3
0.17 (0.11)
0.25 (0.14)
−0.083
0.020
0.054
−0.17 to 0.003
Patient 14
10
1
0.01
0.01
0
NA
NA
NA
N = number of samples evaluated; † data reported in mean (standard deviation); SE = standard error; CI = confidence interval; NA = not applicable since one sample was available.
